Pancreatic cancer is an aggressive malignancy in which early detection is critical but challenging.Because population-wide screening is not feasible, surveillance efforts have increasingly focused on individuals with hereditary susceptibility or a strong family history, who carry a substantially elevated lifetime risk.Evidence from recent prospective cohorts demonstrates that structured surveillance enables detection at earlier stages, improving resectability and survival in selected high-risk groups.Magnetic resonance imaging and endoscopic ultrasonography currently serve as complementary modalities.However, limitations remain, including reduced sensitivity for subtle lesions, variability in risk criteria and surveillance protocols, and uncertainties regarding the economic feasibility.Emerging approaches-including liquid biopsybased biomarkers, artificial intelligence-assisted imaging, and integrated risk stratification models-show promise for enhancing the precision and sustainability of future programs.This review summarizes the current recommendations for pancreatic cancer surveillance in highrisk individuals and highlights evidence from recent studies.
Chun et al. (Mon,) studied this question.